Patients Reshaping the future of patient-centric drug development Strategic partnerships, robust quality systems, and manufacturing know-how will support next-generation therapies with patient-centric designs.
News Samsung Biologics agrees $1.81bn takeover of PolyPeptide Samsung Biologics has agreed to buy PolyPeptide, a Swiss CDMO, in what is thought to be South Korea's largest biopharma acquisition to date.
R&D How automation can drive a competitive advantage for CROs & ... For CROs and CDMOs, automation is key to ensuring long-term success.
R&D Saudi pharma’s rise as a global CDMO destination: Investment... Saudi Arabia is steadily establishing itself as a competitive worldwide destination for contract development and manufacturing.
News Oxford BioMedica confirms private equity takeover talks Oxford BioMedica confirmed this morning that it has received an unsolicited approach from private equity group EQT about a possible takeover.
R&D CDMOs: Their crucial role and how to select one, with Sigma ... Sigma Mostafa, CSO at KBI BioPharma, discusses the role of CDMOs and the important factors companies should consider when selecting one.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.